To Fight Drug Resistant Infections ®
Our mission is to decrease the quantity and severity of infections that cause human suffering and death through the creation and development of novel, targeted, antimicrobial therapies.
The Company’s lead technology, Veriox®, is a proprietary peracid/hydrogen peroxide based non-systemic, non-resistant antimicrobial agent. Veriox® features a novel Mechanism of Action that reduces the likelihood of contributing to resistance against Gram+, Gram-, viral, fungal pathogens and destroys chemical/biological warfare agents.
The Veriox® platform has numerous anti-infective surface, skin and wound care and medical device coating applications. Armis received its first FDA 510(k) clearance for its VeriFixx® Small Bone Implant in November 2020 and submitted an FDA application for its VeriCyn™ prescription wound wash in March 2022. See our Company Overview and Pipeline Sections for more information.
active agent with low
on resistant and preventable
Armis is focused on efficacious, non-systemic products to protect against resistant pathogens and chemical/biological warfare agents. Our products also assist in curing skin infections and improve wound healing